Overexpression of galectin-1 is associated with poor prognosis in human hepatocellular carcinoma following resection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 8, 2012, Pages 1312-1319

  Wu, Han ^a   Chen, Pei ^a   Liao, Rui ^a   Li, Yi Wei ^a   Yi, Yong ^a   Wang, Jia Xing ^a   Sun, Tai Wei ^a   Zhou, Jian ^a   Shi, Ying Hong ^a   Yang, Xin Rong ^a   Jin, Jian Jun ^a   Cheng, Yun Feng ^a   Fan, Jia ^a,b   Qiu, Shuang Jian ^a,b  

^a FUDAN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Galectin 1; Hepatocellular carcinoma; Prognosis; Regulatory T cell; Tumor progression

Indexed keywords

GALECTIN 1;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TISSUE MICROARRAY; TUMOR RECURRENCE; UPREGULATION;

EID: 84864319799     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07130.x     Document Type: Article

References (34)

1. Elserag H, Rudolph K. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
2. Rimassa L, Santoro A. The present and the future landscape of treatment of advanced hepatocellular carcinoma. Dig. Liver Dis. 2010; 42 (Suppl. 3): S273-80.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
4. Lau KS, Dennis JW. N-Glycans in cancer progression. Glycobiology 2008; 18: 750-60.
5. Petretti T, Kemmner W, Schulze B, Schlag PM. Altered mRNA expression of glycosyltransferases in human colorectal carcinomas and liver metastases. Gut 2000; 46: 359-66.
6. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat. Rev. Cancer 2005; 5: 29-41.
7. Potapenko IO, Haakensen VD, Luders T etal. Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Mol. Oncol. 2010; 4: 98-118.
8. Salatino M, Croci DO, Bianco GA, Ilarregui JM, Toscano MA, Rabinovich GA. Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer. Expert. Opin. Biol. Ther. 2008; 8: 45-57.
9. Rabinovich GA, Toscano MA, Jackson SS, Vasta GR. Functions of cell surface galectin-glycoprotein lattices. Curr. Opin. Struct. Biol. 2007; 17: 513-20.
10. Saussez S, Decaestecker C, Lorfevre F etal. High level of galectin-1 expression is a negative prognostic predictor of recurrence in laryngeal squamous cell carcinomas. Int. J. Oncol. 2007; 30: 1109-17.
11. Rorive S, Belot N, Decaestecker C etal. Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma. Glia 2001; 33: 241-55.
12. Cindolo L, Benvenuto G, Salvatore P etal. Galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas. Int. J. Cancer 1999; 84: 39-43.
13. Kondoh N, Hada A, Ryo A etal. Activation of galectin-1 gene in human hepatocellular carcinoma involves methylation-sensitive complex formations at the transcriptional upstream and downstream elements. Int. J. Oncol. 2003; 23: 1575-83.
14. Spano D, Russo R, Di Maso V etal. Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness. Mol. Med. 2010; 16: 102-15.
15. Troncoso MF, Espelt MV, Croci DO etal. Novel roles of galectin-1 in hepatocellular carcinoma cell adhesion, polarization, and in vivo tumor growth. Hepatology 2011; 53: 2097-106.
16. Jung EJ, Moon HG, Cho BI etal. Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int. J. Cancer 2007; 120: 2331-8.
17. Tan W, Zhang WZ, Strasner A etal. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011; 470: 548-53.
18. Juszczynski P, Ouyang J, Monti S etal. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc. Natl. Acad. Sci. U.S.A. 2007; 104: 13134-9.
19. Le QT, Shi G, Cao H etal. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J.Clin. Oncol. 2005; 23: 8932-41.
20. Gao Q, Qiu SJ, Fan J etal. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J.Clin. Oncol. 2007; 25: 2586-93.
21. Xu YF, Yi Y, Qiu SJ etal. PEBP1 downregulation is associated to poor prognosis in HCC related to hepatitis B infection. J. Hepatol. 2010; 53: 872-9.
22. Zhao YM, Wang L, Dai Z etal. Validity of plasma macrophage migration inhibitory factor for diagnosis and prognosis of hepatocellular carcinoma. Int. J. Cancer 2011; 129: 2463-72.
23. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res. 2004; 10: 7252-9.
24. Jelic S, Sotiropoulos GC. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010; 21 (Suppl. 5): v59-64.
25. Pan HW, Ou YH, Peng SY etal. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 2003; 98: 119-27.
26. Nouso K, Kobayashi Y, Nakamura S etal. Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein. J. Gastroenterol. Hepatol. 2011; 26: 1195-200.
27. Chun JM, Kwon HJ, Sohn J etal. Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma. J. Surg. Oncol. 2011; 103: 148-51.
28. Choi GH, Kim DH, Kang CM etal. Prognostic factors and optimal treatment strategy for intrahepatic nodular recurrence after curative resection of hepatocellular carcinoma. Ann. Surg. Oncol. 2008; 15: 618-29.
29. Yang XR, Xu Y, Yu B etal. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 2010; 59: 953-62.
30. Toscano MA, Commodaro AG, Ilarregui JM etal. Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses. J. Immunol. 2006; 176: 6323-32.
31. Van der Leij J, Van den Berg A, Blokzijl T etal. Dimeric galectin-1 induces IL-10 production in T-lymphocytes: an important tool in the regulation of the immune response. J. Pathol. 2004; 204: 511-18.
32. Van der Leij J, Van den Berg A, Harms G etal. Strongly enhanced IL-10 production using stable galectin-1 homodimers. Mol. Immunol. 2007; 44: 506-13.
33. Cedeno-Laurent F, Barthel SR, Opperman MJ, Lee DM, Clark RA, Dimitroff CJ. Development of a nascent galectin-1 chimeric molecule for studying the role of leukocyte galectin-1 ligands and immune disease modulation. J. Immunol. 2010; 185: 4659-72.
34. Sasaki A, Tanaka F, Mimori K etal. Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma. Eur. J. Surg. Oncol. 2008; 34: 173-9.